Chiara Tarantelli
Overview
Explore the profile of Chiara Tarantelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
726
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sartori G, Tarantelli C, Spriano F, Gaudio E, Cascione L, Mascia M, et al.
Br J Haematol
. 2023 Nov;
204(1):191-205.
PMID: 38011941
The DNA damage response (DDR) is the cellular process of preserving an intact genome and is often deregulated in lymphoma cells. The ataxia telangiectasia and Rad3-related (ATR) kinase is a...
12.
Johnson Z, Tarantelli C, Civanelli E, Cascione L, Spriano F, Fraser A, et al.
Cancer Res Commun
. 2023 Apr;
3(4):576-591.
PMID: 37066023
Significance: IOA-244 is a first-in-class non-ATP-competitive, PI3Kδ inhibitor with direct antitumor activity correlated with PI3Kδ expression. The ability to modulate T cells, antitumor activity in various models with limited toxicity...
13.
Arribas A, Napoli S, Cascione L, Barnabei L, Sartori G, Cannas E, et al.
bioRxiv
. 2023 Jan;
PMID: 36711490
Key Points: A mechanism of secondary resistance to the PI3Kδ and BTK inhibitors in B cell neoplasms driven by secreted factors.Resistance can be reverted by targeting ERBB signaling.
14.
Guidetti F, Arribas A, Sartori G, Spriano F, Barnabei L, Tarantelli C, et al.
J Clin Med
. 2023 Jan;
12(2).
PMID: 36675328
Inhibitors of phosphatidylinositol 3-kinase (PI3K) and Bruton tyrosine kinase (BTK) represent a recognized option for the treatment of patients affected by indolent B cell lymphomas. However, small molecules as single...
15.
Barreca M, Lang N, Tarantelli C, Spriano F, Barraja P, Bertoni F
Explor Target Antitumor Ther
. 2023 Jan;
3(6):763-794.
PMID: 36654819
Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies treatment, designed to provide superior efficacy and specific targeting of tumor cells, compared to systemic cytotoxic chemotherapy. Their structure combines...
16.
De Pascale M, Bissegger L, Tarantelli C, Beaufils F, Prescimone A, Mohamed Seid Hedad H, et al.
Eur J Med Chem
. 2023 Jan;
248:115038.
PMID: 36634458
Upregulation of mechanistic target of rapamycin (mTOR) signaling drives various types of cancers and neurological diseases. Rapamycin and its analogues (rapalogs) are first generation mTOR inhibitors, and selectively block mTOR...
17.
Robin P, Barnabei L, Marocco S, Pagnoncelli J, Nicolis D, Tarantelli C, et al.
Biosens Bioelectron X
. 2023 Jan;
13:100302.
PMID: 36589921
The emergence of the coronavirus 2019 (COVID-19) arose the need for rapid, accurate and massive virus detection methods to control the spread of infectious diseases. In this work, a device,...
18.
Spriano F, Tarantelli C, Arribas A, Gaudio E, Cascione L, Aresu L, et al.
Br J Haematol
. 2022 Dec;
200(5):669-672.
PMID: 36484636
No abstract available.
19.
Barreca M, Spano V, Rocca R, Bivacqua R, Abel A, Maruca A, et al.
Eur J Med Chem
. 2022 Oct;
243:114744.
PMID: 36242921
Lymphomas are among the ten most common cancers, and, although progress has been achieved in increasing survival, there is still an unmet need for more effective therapeutic approaches, including better...
20.
Spriano F, Sartori G, Tarantelli C, Barreca M, Golino G, Rinaldi A, et al.
EJHaem
. 2022 Sep;
3(3):764-774.
PMID: 36051080
Inhibitors of the Bromo- and Extra-Terminal domain (BET) family proteins have strong preclinical antitumor activity in multiple tumor models, including lymphomas. Limited single-agent activity has been reported in the clinical...